Lung Cancer
Show only recruiting trials?

GO41854 (Skyscraper 03)
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)
Status
Recruiting
JCP
JCP090
NCT
NCT04513925

BR.31
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer
Status
Closed to Accrual
JCP
BR.31
NCT
NCT02273375

BR.34
A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC)
Status
Closed to Accrual
JCP
BR.34
NCT
NCT03057106

CheckMate 153
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen (CheckMate153)
Status
Closed to Accrual
JCP
JCP005
NCT
NCT02066636

MK-3475-495
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)
Status
Closed to Accrual
JCP
JCP057
NCT
NCT03516981

MK-3475-789
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
Status
Closed to Accrual
JCP
JCP045
NCT
NCT03515837
Filter Clinical Trials by:
Biomarkers: